Total homocysteine and cardiovascular disease

Journal of Internal Medicine

Volumn 246, Issue 5, 1999, Pages 425-454

  Nygård, Ottar ^b   Vollset, S E ^c   Refsum, H ^c   Brattstrom L ^a   Ueland, P M ^c  

^a KALMAR COUNTY HOSPITAL   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NONE

Author keywords

Atherosclerosis; Cardiovascular disease; Homocysteine; Pathogenesis

Indexed keywords

HOMOCYSTEINE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0001704784     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00512.x     Document Type: Review

References (389)

1. 1 Butz LW, du Vigneaud V. The formation of a homologue of cystine by the decomposition of methionine with sulfuric acid. J Biol Chem 1932; 99: 135-42.
2. 2 Case records of the Massachusets General Hospital. Marked cerebral symptoms following a limp of three months' duration. New Engl J Med 1933; 209: 1063-6.
3. 3 McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-28.
4. 4 Gerritsen T, Vaughn JG, Weisman HA. The identification of homocysteine in the urine. Biochem Biophys Res Commun 1962; 9: 493-6.
5. 5 Carson NAJ, Neill DW. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child 1962; 37: 505-13.
6. 6 Mudd SH, Levy HL, et al. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D. eds. The Metabolic and Molecular Bases of Inherited Disease, 1st edn, Vol 1. New York: McGraw-Hill, 1995: 1279-327.
7. 7 Schimke RN, McKusick VA, Huang T, Pollack AD. Homocystinuria. Studies of 20 families with 38 affected members. JAMA 1965; 193: 87-95.
8. 8 McCully KS. Homocysteine theory of arteriosclerosis: Development and current status. Atherosclerosis Rev 1983; 11: 157-246.
9. 9 Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985; 37: 1-31.
10. 10 McCully KS. Homocysteine, folate, vitamin B6, and cardiovascular disease. JAMA 1998; 279: 392-3.
11. 11 McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22: 215-27.
12. 12 Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
13. 13 Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
14. 14 Boers GHJ. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997; 78: 520-2.
15. 15 D'Angelo A, Mazzola G, Crippa L, Fermo I, D'Angelo SV. Hyperhomocysteinemia and venous thromboembolic disease. Haematologica 1997; 82: 211-9.
16. 16 Selhub J. Mild hyperhomocysteinemia and arterial occlusive disease. Haematologica 1997; 82: 129-32.
17. 17 Ueland PM. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev 1982; 34: 223-53.
18. 18 Wendel U, Bremer HJ. Betaine in the treatment of homocystinuria due to 5.10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr 1984; 142: 147-50.
19. 19 Fowler B. Disorders of homocysteine metabolism. J Inher Metab Dis 1997; 20: 270-85.
20. 20 Mato JM, Alvarez L, Ortiz P, Pajares MA. S-Adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 1997; 73: 265-80.
21. 21 Sunden SLF, Renduchintala MS, Park EI, Miklasz SD, Garrow TA. Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Arch Biochem Biophys 1997; 345: 171-4.
22. 22 Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228-37.
23. 23 Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum. Methods and clinical applications. Clin Chem 1993; 39: 1764-79.
24. 24 Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995; 41: 340-2.
25. 25 Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985; 31: 624-8.
26. 26 Kang S-S, Wong PWK, Malinow MR, Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992; 12: 279-98.
27. 27 Stein WH, Moore S. The free amino acids of human blood plasma. J Biol Chem 1954; 211: 915-26.
28. 28 Kang S-S, Wong PWK, Becker N. Protein-bound homocyst(e)ine in normal subjects and in patients with homocystinuria. Pediatr Res 1979; 13: 1141-3.
29. 29 Refsum H, Ueland PM, Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin Chem 1989; 35: 1921-7.
30. 30 Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993; 39: 263-71.
31. 31 Nygård O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
32. 32 Nygård O, Nordrehaug JE, Refsum H, Farstad M, Ueland PM, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
33. 33 Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. The effect of blood sample aging and food consumption on plasma total homocysteine levels. Clin Chim Acta 1992; 207: 119-28.
34. 34 Candito M, Aubin-Brunet V, Beaulieu F, Chevalier T, Pringuey D, Darcourt G. Increased postprandial homocysteinemia in a group of depressed patients. Amino Acids 1997; 12: 315-21.
35. 35 Fermo I, De Vecchi E, D'Angelo SV, D'Angelo A, Paroni R. Total plasma homocysteine: influence of some common physiological variables. Amino Acids 1993; 5: 17-21.
36. 36 Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum H. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy subjects. J Nutr 1994; 124: 1934-41.
37. 37 Leppänen EA, Gasbäck R. Experimental basis of standardized specimen collection: effect of posture on blood picture. Eur J Haematol 1988; 40: 222-6.
38. 38 Andersson A, Isaksson A, Hultberg B. Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem 1992; 38: 1311-5.
39. 39 Willems HP, Bos GM, Gerrits WB, den Heijer M, Vloet S, Blom HJ. Acidic citrate stabilizes blood samples for assay of total homocysteine. Clin Chem 1998; 44: 342-5.
40. 40 Daskalakis I, Lucock MD, Anderson A, Wild J, Schorah CJ, Levene MI. Determination of plasma total homocysteine and cysteine using HPLC with fluorescence detection and an ammonium 7-fluoro-2,1,3-benzoxadiazole-4-sulphonate (SBD-F) derivatization protocol optimized for antioxidant concentration, derivatization reagent concentration, temperature and matrix pH. Biomed Chromatogr 1996; 10: 205-12.
41. 41 Kittner SJ, Malinow MR, Seipp MJ, Upson B, Hebel JR. Stability of blood homocyst(e)ine under epidemiological field conditions. J Clin Lab Anal 1995; 9: 75-6.
42. 42 Israelsson B, Brattström L, Refsum H. Homocysteine in frozen plasma samples - a short cut to establish hyperhomocysteinaemia as a risk factor for arteriosclerosis. Scand J Clin Lab Invest 1993; 53: 465-9.
43. 43 Garg UC, Zheng Z-J, Folsom AR, et al. Short-term and long-term variability of plasma homocysteine measurement. Clin Chem 1997; 43: 141-5.
44. 44 Cobbaert C, Arentsen JC, Mulder P, Hoogerbrugge N, Lindemans J. Significance of various parameters derived from biological variability of lipoprotein (a). homocysteine, cysteine, and total antioxidant status. Clin Chem 1997; 43: 1958-64.
45. 45 Clarke R, Khaw KT, Woodhouse P, et al. Variability and determinants of plasma total homocysteine in an elderly population. Clin Chem 1998; 44: 102-7.
46. 46 Eckfeldt JH, Chambless LE, Shen YL. Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med 1994; 118: 496-500.
47. 47 Brenton DP, Cusworth DC, Gaull GE. Homocystinuria: metabolic studies on 3 patients. J Pediatr 1965; 67: 58-68.
48. 48 Fowler B, Sardharwalla IB, Robins AJ. The detection of heterozygotes for homocystinuria by oral loading with L-methionine. Biochem J 1971; 122: 23-4.
49. 49 Sardharwalla IB, Fowler B, Robins AJ, Komrower GM. Detection of heterozygotes for homocystinuria. Study of sulphur-containing amino acids in plasma and urine after L-methionine loading. Arch Dis Child 1974; 49: 553-9.
50. 50 Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-15.
51. 51 Boers GHJ, Fowler B, Smals AGH, et al. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet 1985; 69: 164-9.
52. 52 Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
53. 53 Kozich V, Janosik M, Sokolova J, et al. Analysis of CBS alleles in Czech and Slovak patients with homocystinuria: report on three novel mutations E176K, W409X and 1223+37 del99. J Inherit Metab Dis 1997; 20: 363-6.
54. 54 Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI family heart study. Atherosclerosis 1995; 116: 147-51.
55. 55 Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997; 277: 1775-81.
56. 56 van der Griend R, Haas FJLM, Duran M, Biesma DH, Menwissen OJAT, Banga JD. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998; 132: 67-72.
57. 57 Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RBJ, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York: Marcel Dekker, Inc., 1992: 183-236.
58. 58 Wilcken DEL. Homocysteine and vascular disease. Med L Aust 1998; 168: 431-2.
59. 59 Carson NAJ, Dent CE, Field CMB, Gall GE. Homocystinuria: Clinical and pathological review of ten cases. J Pediatr 1965; 66: 565-83.
60. 60 Gibson JB, Carson NAJ, Neill DW. Pathological findings in homocystinuria. J Clin Pathol 1964; 17: 427-37.
61. 61 Schimke RN, McKusick VA, Huang T, Pollack AD. Homocystinuria. JAMA 1965; 193; 711-9.
62. 62 Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria: an enzymatic defect. Science 1964; 143: 1443-5.
63. 63 Dawson PA, Cox AJ, Emmerson BT, Dudman NPB, Kraus JP, Gordon RB. Characterisation of five missense mutations in the cystathionine beta-synthase gene from three patients with B-6-nonresponsive homocystinuria. Eur J Hum Genet 1997; 5: 15-21.
64. 64 Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE. Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun 1972; 46: 905-12.
65. 65 Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996; 19: 589-94.
66. 66 Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cbIG complementation group of folate/ cobalamin disorders. Hum Mol Genet 1996; 5: 1867-74.
67. 67 Kraus JP, Le K, Swaroop M, et al. Human cystathionine beta-Synthase cDNA - sequence, alternative splicing and expression in cultured cells. Hum Mol Genet 1993; 2: 1633-8.
68. 68 Goyette P, Summer JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1994; 7: 195-200.
69. 69 Chen LH, Liu ML, Hwang HY, Chen LS, Korenberg J, Shane B. Human methionine synthase: cDNA cloning, gene localisation, and expression. J Biol Chem 1997; 272: 3628-34.
70. 70 Garrow TA. Purification, kinetic properties, and cDNA cloning of mammalian betaine-homocysteine methyltransferase. J Biol Chem 1996; 271: 22 831-8.
71. 71 Giusti B, Comeglio P, Attanasio M, et al. Different distribution of the double mutant 'T833C/68 bp insertion' in cystathionine beta-synthase gene in Northern and Southern Italian populations. Thromb Haemost 1997; 78: 1293.
72. 72 Kim CE, Gallagher PM, Guttormsen AB, et al. Functional modeling of vitamin responsiveness in yeast: a common pyridoxine-responsive cystathionine beta-synthase mutation in homocystinuria. Hum Mol Genet 1997; 6: 2213-21.
73. 73 Sperandeo MP, Candito M, Sebastio G, et al. Homocysteine response to methionine challenge in four obligate heterozygotes for homocystinuria and relationship with cystathionine beta-synthase mutations. J Inherit Metab Dis 1996; 19: 351-6.
74. 74 Scott J, Weir D. Homocysteine and cardiovascular disease. QJM 1996; 89: 561-3.
75. 75 Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down's syndrome: an atheroma-free model? Br Med J 1977; 2: 226-8.
76. 76 Kang SS, Wong PWK, Zhou J, et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988; 37: 611-3.
77. 77 Kang S-S, Zhou J, Wong PWK, Kowallsyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
78. 78 Frosst P, Blom HJ, Milos R, et al. Identification of a candidate genetic risk factor for vascular disease: a common mutation at the methylenetetrahydrofolate reductase locus. Nat Genet 1995; 10: 111-3.
79. 79 Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5, 10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-50.
80. 80 Jacques PF, Bostom AG, Williams RR, et al. Relation between folute status, a common mutation In methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
81. 81 Kang S-S. Critical points for determining moderate hyperhomocyst(e)inemia. Eur J Clin Invest 1995; 25: 806-8.
82. 82 Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/L). The Hordaland Homocysteine Study. J Clin Invest 1996; 98: 2174-83.
83. 83 Woodside JV, Yarnell JWG, Mcmaster D, et al. Vitamin B6 status, MTHFR and byperhomocysteinaemia. QJM 1997; 90: 551-2.
84. 84 Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79: 119-21.
85. 85 Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1998; 136: 347-54.
86. 86 Stevenson RE, Schwartz CE, Du YZ, Adams MJJ. Differences in methylenetetrahydrofolate reductase genotype frequencies, between whites and blacks. Am J Hum Genet 1997; 60: 229-30.
87. 87 Hegele RA, Tully C, Young TK, Connelly PW. V677 mutation of methylenetetrahydrofolate reductase and cardiovascular disease in Canadian Inuit. Lancet 1997; 349: 1221-2.
88. 88 Sacchi E, Tagliabue L, Duca F, Mannucci PM. High frequency of the C677T mutaition in the methylenetetrahydrofolate redudase (MTHFR) gene in Northern Italy. Thromb Haemost 1997; 78: 963-4.
89. 89 Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996; 58: 17-20.
90. 90 Vermaak WJ, Ubbink JB, Delport R, Becker PJ, Bissbort SH, Ungerer JP. Ethnic immunity to coronary heart disease? Atherosclerosis 1991; 89: 155-62.
91. 91 Ubbink JB, Delport R, Vermaak WJ. Plasma homocysteine concentrations in a population with a low coronary heart disease prevalence. J Nutr 1996; 126 (Suppl. 4): 1254S-7S.
92. 92 Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circ Res 1989; 79: 1180-8.
93. 93 Berg K, Malinow MR, Kierulf P, Upson B. Population variation and genetics of plasma homocyst(e)ine level. Clin Genet 1992; 41: 315-21.
94. 94 Kang S-S, Wang PWK, Zhou J, Cook HY. Preliminary report: Total homocyst(e)ine in plasma and amniotic fluid of pregnant women. Metabolism 1986; 35: 889-91.
95. 95 Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52.
96. 96 Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549-54.
97. 97 Andersson A, Brattström L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992; 22: 79-87.
98. 98 Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamin and folate levels in normal subjects. Clin Chem 1994; 40: 873-81.
99. 99 Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994; 236: 631-41.
100. 100 Tonstad S, Refsum H, Ueland PM. Association between plasma total homocysteine and parental history of cardiovascular disease in children with familial hypercholesterolemia. Circulation 1997; 96: 1803-8.
101. 101 Andersson A, Hultberg B, Brattström L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992; 30: 377-9.
102. 102 Steegers-Theunissen RPM, Boers GHJ, Blom H, Trijbels FJM, Eskes TKAB. Hyperhomocysteinemia and recurrent spontaneous abortion or abruptio placenta. Lancet 1992; 339: 1122-3.
103. 103 Wouters MGAJ, Boers GHJ, Blom H, et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993; 60: 820-5.
104. 104 Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
105. 105 Bostom A, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995; 116: 59-62.
106. 106 Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996; 56: 41-6.
107. 107 Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52: 495-502.
108. 108 Guttormsen AB, Svarstad E, Ueland PM, Refsum H. Elimination of homocysteine from plasma in subjects with endstage renal failure. Irish J Med Sci 1995; 164 (Suppl. 15): 8.
109. 109 House JD, Brosnan MGEE, et al. Renal homocysteine metabolism. In: Odonovan DJ, Endou H, Schoolwerth AC, Tizianello A, Walls J, eds. Nutritional and Acid-Base Aspects of Amino Acid Metabolism. Basel: Karger, 1997: 79-84.
110. 110 House JD, Brosnan ME, Brosnan JT. Characterization of homocysteine metabolism in the rat kidney. Biochem J 1997; 328: 287-92.
111. 111 van Guldener C, Donker AJM, Jakobs C, Teerlink T, de Meer K, Stehouwer CDA. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998; 54: 166-9.
112. 112 Norlund L, Grubb A, Fex G, et al. The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 1998; 36: 175-8.
113. 113 Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B-6, B-12, and folate. Am J Epidemiol 1996; 143: 845-59.
114. 114 Jacques PF, Sulsky SI, Sadowski JA, Phillips JCC, Rush D, Willett WC. Comparison of micronutrient intake measured by a dietary questionnaire and biochemical indicators of micronutrient status. Am J Clin Nutr 1993; 57: 182-9.
115. 115 Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
116. 116 Koehler KM, Pareotubbeh SL, Liang HC, Romero LJ, Baumgartner RN, Garry PJ. Some vitamin sources relating to plasma homocysteine provide not only folate but also vitamins B-12 and B-6. J Nutr 1997; 127: 1534-5.
117. 117 Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67: 263-70.
118. 118 Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 1993; 7: 1344-53.
119. 119 Joosten E, van den Berg A, Riezler R, et al. Metabolic evidence that deficiencies of vitamin B12, folate and vitamin B6 occur commonly in the elderly. Am J Clin Nutr 1993; 58: 468-76.
120. 120 Miller JW, Ribaya-Mercado JD, Russell RM, et al. Effect of vitamin-B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992; 55: 1154-60.
121. 121 Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57: 47-53.
122. 122 Tucker KL, Selhub J, Wilson PWF, Rosenbers IH. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J Nutr 1996; 126: 3025-31.
123. 123 Nygård O, Refsum H, Ueland PM, et al. Coffee consumption and total plasma homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr 1997; 65: 136-43.
124. 124 Vollset SE, Nygård O, Kvåle G, et al. The Hordaland Homocysteine Study: lifestyle and total plasma homocysteine in Western Norway. In: Graham I, Refsum H, Rosenberg IH, Ueland P,eds. Homocysteine Metabolism: from Basic Science to Clinical Medicine. Boston: Kluwer Academic Publishers, 1997: 177-82.
125. 125 Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. Acohol Clin Exp Res 1993; 17: 687-9.
126. 126 Cravo ML, Glória LM, Selhub J, et al. Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr 1996; 63: 220-4.
127. 127 Barak AJ, Beckenhauer HC, Tuma DJ. Betaine, ethanol, and the liver: a review. Alcohol 1996; 13: 395-8.
128. 128 Hidiroglou N, Camilo ME, Beckenhauer HC, et al. Effect of chronic alcohol ingestion on hepatic folate distribution in the rat. Biochem Pharmacol 1994; 47: 1561-6.
129. 129 Gloria L, Cravo M, Camilo ME, et al. Nutritional deficiencies in chronic alcoholics: relation to dietary intake and alcohol consumption. Am J Gastroenterol 1997; 92: 485-9.
130. 130 Refsum H, Ueland PM. Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci 1990; 11: 411-6.
131. 131 Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H. Hyperhomocysteinemia in cyclosporin-treated renal transplant recipients. Transplantation 1996; 61: 509.
132. 132 Carlsen SM, Følling I, Grill V, Bjerve KS, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997; 57: 521-7.
133. 133 Hoogeveen EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CDA. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J Intern Med 1997; 242: 389-94.
134. 134 Carl GF, Hudson FZ, Mcguire BS. Phenytoin-induced depletion of folate in rats originates in liver and involves a mechanism that does not discriminate folate form. J Nutr 1997; 127: 2231-8.
135. 135 Blankenhorn DH, Malinow MR, Mack WJ. Colestipol plus niacin therapy elevates plasma homocyst(e)ine levels. Coron Art Dis 1991; 2: 357-60.
136. 136 Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996; 129: 42-9.
137. 137 Tonstad S, Refsum H, Ose L, Ueland PM. The C677T mutation in the methyleneletrahydrofolate reductase gene predisposes to hyperhomocystetnemia in children with familial hypercholesterolemia treated with cholestyramine. J Pediatr 1998; 132: 365-8.
138. 138 Basu TK, Mann S. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects. J Nutr 1997; 127: 117-21.
139. 139 Ubbink JB, van der Merwe A, Delport R, et al. The effect of a subnormal vitamin B6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177-84.
140. 140 Drell W, Welch AD. Azaribine-homocystmemia-thrombosis in historical perspectives. Pharmac Ther 1989; 41: 195-206.
141. 141 Slavik M, Hyanek J, Elis J, Homolka J. Typical hyperaminoaciduria after high doses of 6-azauridine triacetate. Biochem Pharmacol 1969; 18: 1782-4.
142. 142 Shupack JL, Grieco AJ, Epstein AM, Sansaricq C, Snyderman SE. Azaribine, homocystinemia, and thrombosis. Arch Dermatol 1977; 113: 1301-2.
143. 143 Daly D, Miller JW, Nadeau MR, Selhub J. The effect of L-dopa administration and folate deficiency on plasma homocysteine concentrations in rats. J Nutr Biochem 1997; 8: 634-40.
144. 144 Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-Dopa and the catechol-Omethyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997; 20: 55-66.
145. 145 Anker G, Lønning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60: 365-8.
146. 146 Lien EA, Anker G, Lønning PE, Refsum H, Ueland PM. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochem Soc Trans 1997; 46: 247-9.
147. 147 van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994; 24: 733-6.
148. 148 van der Mooren MJ, Demacker PN, Blom HJ, de Rijke YB, Rolland R. The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women. Fertil Steril 1997; 67: 67-73.
149. 149 Mijatovic V, Kenemans P, Jakobs C, van Baal WM, Peters-Muller ER, van der Mooren MJ. A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998; 91: 432-6.
150. 150 Steegers-Theunissen RPM, Boers GHJ, Steegers EAP, Trijbels FJM, Thomas CMG, Eskes TKAB. Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study. Contraception 1992; 45: 129-39.
151. 151 Wong PWK, Kang SS. Accelerated atherosclerosis. Am J Med 1988; 84; 1093-4.
152. 152 Brattström L, Israelsson B, Olsson A, Andersson A, Hultberg B. Plasma homocysteine in women on oral oestrogen-containing contraceptives and in men with oestrogen-treated prostatic carcinoma. Scand J Clin Lab Invest 1992; 52: 283-7.
153. 153 Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 1998; 83: 550-3.
154. 154 Kang S-S, Wong PWK, Curley K. The effect of D-penicillamine on protein-bound homocyst(e)ine in homocystinurics. Pediatr Res 1982; 16: 370-2.
155. 155 Rang S-S, Wong PWK, Glickman PB, MacLeod CM, Jaffe IA. Protein-bound homocyst(e)ine in patients with rheumatoid arthritis undergoing D-penicillamine treatment. J Clin Pharmacol 1986; 26: 712-5.
156. 156 Wiklund O, Pager G, Andersson A, Lundstam U, Masson P, Hultberg B. N-Acetyleysteine treatment lowers plasma homocysteine but not serum lipoprotein (a) levels. Atherosclerosis 1996; 119; 99-106.
157. 157 Lauterburg BH, Nguyen T, Hartmann B, Junker E, Küpfer A, Cerny T. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 1994; 35: 132-6.
158. 158 Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia. Changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991; 51: 828-35.
159. 159 Weinstein GD. Biochemical and pathophysiological rationale for amethopterin in psoriasis. NY Acad Sci 1971; 186: 452-66.
160. 160 McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99: 469-75.
161. 161 Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter to antifolate effect. A study on psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther 1989; 46: 510-20.
162. 162 Nedrebø BG, Ericsson UB, Nygård O, et al. Plasma total homocysteine in hyperthyroid and hypothyroid patients. Metabolism 1998; 47: 89-93.
163. 163 Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR. Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism 1998; 47: 686-9.
164. 164 Hultberg B, Agardh E, Andersson A, et al. Increased levels of plasma homocysteine are associated with nephropathy but not severe retinopathy in type 1 diabetes mellitus. Scand J Lab Clin Invest 1991; 51; 277-82.
165. 165 Hultberg B, Agardh CD, Agardh E, Lovestam-Adrian M. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study. Scand J Clin Lab Invest 1997; 57: 595-600.
166. 166 Robinson K, Dennis VW. From microalbuminuria to hyperhomocysteinemia. Kidney Int 1998; 54: 281-2.
167. 167 Lydakis C, Lip GYH. Microalbuminuria and cardiovascular risk. QJM 1998; 91: 381-91.
168. 168 Chico A, Perez A, Cordoba A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998; 41: 684-93.
169. 169 Lanfredini M, Fiorina P, Peca MC, et al. Fasting and post-methionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus. Metabolism 1998; 47: 915-21.
170. 170 Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133-8.
171. 171 Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12. folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346: 85-9.
172. 172 Brattström L. Vitamins as homocysteine-lowering agents. J Nutr 1996; 126: 1276S-80S.
173. 173 Ubbink JB. The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia. J Inherited Metab Dis 1997; 20: 316-25.
174. 174 Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993; 13: 1253-60.
175. 175 van den Berg M, Franken DG, Boers GHJ, et al. Combined vitamin B-6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg 1994; 20: 933-40.
176. 176 Brattström LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988; 48: 215-21.
177. 177 Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927-33.
178. 178 Franken DG, Boers GH, Blom HJ, Trijbels JM. Effect of various regimens of vitamin B6 and folic acid on mild hyperhomocysteinaemia in vascular patients. J Inherit Metab Dis 1994; 17: 159-62.
179. 179 Homocysteine Lowering Trialist' Collaboration. Lowering blood homocysteine with folic acid based supplements: metaanalysis of randomised trials. Br Med J 1998; 316: 894-8.
180. 180 Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic-acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997; 17: 1157-62.
181. 181 Jacob RA, Mei-Miau W, Henning S, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr 1994; 124: 1072-80.
182. 182 O'Keefe CA, Bailey LB, Thomas EA, et al. Controlled dietary folate affects folate status in nonpregnant women. J Nutr 1995; 125: 2717-25.
183. 183 Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, Scott JM. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. QJM 1997; 90: 519-24.
184. 184 Woodside JV, Yarnell JWG, Memaster D, et al. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr 1998; 67: 858-66.
185. 185 Rubba P, Mercuri M, Faccenda F, et al. Premature carotid atherosclerosis: does it occur in both familial hypercholesterolemia and homocystinuria? Stroke 1994; 25: 943-50.
186. 186 Boers GHJ. Hyperhomnocysteinemia: a newly recognized risk factor for vascular disease. Neth J Med 1994; 45: 34-41.
187. 187 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing Folic acid intakes. JAMA 1995; 274: 1049-57.
188. 188 Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.
189. 189 Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87: 1107-13.
190. 190 Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
191. 191 Tonstad S, Joakimsen O, Stenslandbugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Dis 1996; 16: 984-91.
192. 192 Voutilainen S, Alfthan G, Nyyssonen K, Salonen R, Salonen JT. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness. Ann Med 1998; 30: 300-6.
193. 193 van den Berg M, Stehouwer CDA, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996; 16: 165-71.
194. 194 Verhoef P, Kok FJ, Kruyssen DACM, et al. Plasma total homocysteine, B vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-95.
195. 195 von Eckardstein A, Malinow MR, Upson B, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994; 14: 460-4.
196. 196 Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991; 69: 527-34.
197. 197 Malinow MR. Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. J Nutr 1996; 126: 1238S-43S.
198. 198 Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59: 940-8.
199. 199 Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
200. 200 Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest JJ. Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol 1995; 75: 1107-11.
201. 201 Ambrosi P, Garcon D, Riberi A, et al. Association of mild hyperhomocysteinemia with cardiac graft vascular disease. Atherosclerosis 1998; 138: 347-50.
202. 202 Willems FF, Aengevaeren WRM, Jukema JW, et al. Hyperhomocysteinemia and progression of coronary atherosclerosis [abstract]. Neth J Med 1998; 52: S36-S37.
203. 203 Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-81.
204. 204 Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-9.
205. 205 Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Serum total homocysteine and coronary heart disease in middle-aged British men [abstract]. Heart 1996; 75: P53.
206. 206 Whincup PH, Refsum H, Perry IJ, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men [abstract]. Neth J Med 1998; 52: S36.
207. 207 Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-8.
208. 208 Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-4.
209. 209 Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infartion. Am J Cardiol 1996; 77: 759-61.
210. 210 Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26: 795-800.
211. 211 Nygård O. The Hordaland Homocysteine Studies. Determinants and prognostic value of plasma total homocysteine [dissertation], Bergen: 1998.
212. 212 Meleady R, Lindgren A, Boers GHJ, et al. Plasma homocysteine as a prognostic risk factor for vascular disease [abstract]. Eur Heart J 1998; 19: 214.
213. 213 Al-Obaidi M, Noble M, Conroy R, Graham I, Stubbs P. Admission plasma homocysteine predicts long-term mortality in patients with acute coronary ischemia [abstract]. Eur Heart J 1998; 19: P1040.
214. 214 Bostom AG, Silbershatz H, Jacques PF, et al. Serum total homocysteine levels predict all cause and cardiovascular disease mortality in elderly Framingham men and women [abstract]. Circulation 1998; 97: 818.
215. 215 Hoogeveen EK, Kostense PJ, de Vegt F, et al. Hyperhomocysteinemia is a risk factor for mortality: The Hoorn Study [abstract]. Neth J Med 1998; 52: S8.
216. 216 Brattström L, Tengborn L, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-7.
217. 217 Simioni P, Prandoni P, Burlina A, et al. Hyperhomocysteinemia and deep-vein thrombosis - a case-control study. Thromb Haemost 1996; 76: 883-6.
218. 218 den Heijer M, Blom HJ, Gerrits WBJ, et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-5.
219. 219 Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 1995; 15: 1321-3.
220. 220 den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
221. 221 den Heijer M. Hyperhomocysteinemia and venous thrombosis [dissertation]. University of Leiden. The Netherlands, 1997; 120.
222. 222 Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow RM, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.
223. 223 Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res 1993; 70: 123-9.
224. 224 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-3.
225. 225 Fermo I, D'Angelo SV, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747.
226. 226 Cattaneo M, Martinelli I, Mannucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 335: 974-5.
227. 227 Tazi Z, Cacoub P, Koskas F, et al. Value of an extensive biological study in venous or arterial thrombosis. Presse Med 1996; 25: 531-6.
228. 228 Wouters MGAJ, Moorrees MTEC, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25: 801-5.
229. 229 Kang S-S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest 1986; 77: 1482-6.
230. 230 Araki A, Sako Y, Fukushima Y, Matsumoto M, Asada T, Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989; 79: 139-46.
231. 231 Bergmark C, Mansoor MA, Swedenborg J, de Faire U, Svardal AM, Ueland PM. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50. Effect of smoking and extent of disease. Eur J Vasc Surg 1993; 7: 391-6.
232. 232 Chauveau P, Chadefaux B, Coudé M, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43 (Suppl. 41): S72-S77.
233. 233 Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554-8.
234. 234 Gomberg-Maitland M, Frishman WH. Thyroid hormone and cardiovascular disease. Am Heart J 1998; 135 (2 pt 1): 187-96.
235. 235 van den Berg M, Boers GHJ, Franken DG, et al. Hyperhomocysteinaemia and endothelial dysfunction: young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-81.
236. 236 Lubec B, Labudova O, Hoeger H, et al. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 1996; 94: 2620-5.
237. 237 de Jong SC, Stehouwer CDA, van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost 1997; 78: 1332-7.
238. 238 Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
239. 239 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
240. 240 Gemmati D, Serino ML, Moratelli S, Mari R, Ballerini G, Scapoli GL. Coexistence of antithrombin deficiency, factor V Leiden and hyperhomocysteinemia in a thrombotic family. Blood Coagul Fibrinol 1998; 9: 173-6.
241. 241 Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996; 334: 763-8.
242. 242 Cattanco M, Tsai MY, Bucciarelli P, et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (Factor V. Q (506)). Arterioscler Thromb Vasc Biol 1997; 17: 1662-6.
243. 241 Kluijtmans LAJ, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 254-8.
244. 244 Franken DG. Hyperhomocysteinemia: inherited causes and effects of treatment [dissertation]. University Hospital Nijmegen, The Netherlands. 1996; 175.
245. 245 Franken DG, Boers GHJ, Blom HJ, Cruysberg JRM, Trijbels FJM, Hamel BCJ. Prevalence of familial mild hyperhomocysteinemia. Atherosclerosis 1996; 125: 71-80.
246. 246 Genest JJJ, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Anterioscler Thromb 1991; 11: 1129-36.
247. 247 Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994; 40: 552-61.
248. 248 Tonstad S, Refsum H, Sivertsen M, Christophersen B, Ose L, Ueland PM. Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives. Pediatr Res 1996; 40: 47-52.
249. 249 Rubbanyi GM. The role of the endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22: S1-S14.
250. 250 De Meyer GR, Herman AG. Vascular endothelial dysfunction. Prog Cardiovasc Dis 1997; 39: 325-42.
251. 251 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
252. 252 Benzuly KH, Padget RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 89: 1810-8.
253. 253 Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-11.
254. 254 van der Molen EF, Hiipakka MJ, van Lith-Zanders H, et al. Homocysteine metabolism in endothelial cells of a patient homozygous for cystathionine beta-synthase (CS) deficiency. Thromb Haemost 1997; 78: 827-33.
255. 255 Rock G, Wells P. New concepts in coagulation. Crit Rev Clin Lab Sci 1997; 34: 475-501.
256. 256 Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997; 77: 408-23.
257. 257 Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-16.
258. 258 Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-9.
259. 259 Hajjar KA, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin II tail domain - direct modulation by homocysteine. J Biol Chem 1998; 273: 9987-93.
260. 260 Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein-C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
261. 261 Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein-C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
262. 262 Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-6.
263. 263 Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-6.
264. 264 Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-33.
265. 265 Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-18.
266. 266 Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982; 16: 490-3.
267. 267 Panganamala RV, Karpen CW, Merola AJ. Peroxide mediated effects of homocysteine on arterial prostacyclin synthesis. Prostagland Leuk Med 1986; 22: 349-56.
268. 268 Quéré I, Habib A, Tobelem G, et al. Inhibition of cyclooxygenase activity in human endothelial cells by homocysteine. In: Samuelsson B, Ramwell PW, Paoletti R, Folco G, Granstrom E, Nicosia S,eds. Prostaglandins and Related Compounds, Vol 23. New York: Raven Press, 1995: 397-9.
269. 269 Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand Factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81: 683-9.
270. 270 Lentz SR, Sobey CG, Piegors DJ, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 24-9.
271. 271 Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
272. 272 Lentz SR, Malinow MR, Piegors DJ, Bhopatkarteredesai M, Faraci FM, Heistad HD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol 1997; 17: 2930-4.
273. 273 Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homuzygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-8.
274. 274 Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
275. 275 Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-4.
276. 276 Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhornocysteinemia and endothelial dysfunction. Lancet 1998; 351: 36-7.
277. 277 Bellamy MF, Ramsey MW, Goodfellow J, et al. Hyperhomocysteinemia and endothelial dysfunction with low vitamin B-12/folate status [abstract]. Circulation 1996; 94 (Suppl. 1): 1-462.
278. 278 Bellamy MF, McDowell IFW, Ramsey MW, Brownlee M, Lewis MJ. Folic acid supplements lower plasma homocysteine and improve flow-mediated endothelial function in healthy adults. Neth J Med 1998; 52 (Suppl.): S14.
279. 279 Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-43.
280. 280 Harker LA, Ross R, Slichter SJ, Scott CK. Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-41.
281. 281 Hladovec J. Experimental homocystinemia, endothelial lesions and thrombosis. Blood Vessels 1979; 16: 202-5.
282. 282 Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homncysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731-9.
283. 283 Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-21.
284. 284 DeGroot PG, Willems C, Boers GHJ, Gonsalves MD, van Aken WG, van Mourik JA. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983; 113: 405-10.
285. 285 Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-6.
286. 286 Dudman NPB, Hicks C, Wang J, Wilcken DEL. Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 1991; 91: 77-83.
287. 287 Berman RS, Martin W. Arterial enduthelial barrier dysfunction - Actions of homocysteine and the hypoxanthinexanthine oxidase free radical generating system. Br J Pharmacol 1993; 108: 920-6.
288. 288 Jones BG, Rose FA, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994; 105: 165-70.
289. 289 Reddy GSR, Wilcken DHL. Experimental homocysteinemia in pigs: comparison with studies in sixteen homocystinuric patients. Metabolism 1982; 31: 778-83.
290. 290 Hladovec J, Sommerova Z, Pisarikova A. Homocysteinemia and endothelial damage after methionine load. Thromb Res 1997; 88: 361-4.
291. 291 Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci. USA 1994; 91: 6369-73.
292. 292 Wang H, Yoshizumi M, Lai KH, et al. Inhibition of growth and p21 (ras) methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380-5.
293. 293 Hultberg B, Andersson A, Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicology 1997; 123: 33-40.
294. 294 Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997; 8: 320-8.
295. 295 Mansoor MA, Bergmark C, Svardal AM, Lønning PE, Ueland PM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995; 15: 232-40.
296. 296 Andersson A, Lindgren A, Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem 1995; 41: 361-6.
297. 297 Dudman NPB, Wilcken DEL. Increased plasma copper in patients with homocystinuria due to cystathionine beta synthase deficiency. Clin Chim Acta 1983; 127: 105-13.
298. 298 Freedman JE, Frei B, Welch GN, Loscalzo J. Glutathione peroxidase potentiales the inhibition of platelet function by s-nitrosthiols. J Clin Invest 1995; 96: 394-400.
299. 299 Upchurch GR, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-7.
300. 300 Upchurch GR, Welch GN, Fabian AJ, Pigazzi A, Keaney JF, Loscalzo J. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis 1997; 132: 177-85.
301. 301 Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 1996; 54: 1-30.
302. 302 Upchurch GR, Welch GN, Loscalzo J. Homocysteine, EDRF and endothelial function. J Nutr 1996; 126 (Suppl. 4): S1290-S1294.
303. 303 Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
304. 304 Stocker R. Lipoprotein oxidation: mechanisms, aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 1994; 5: 422-33.
305. 305 Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20: 707-27.
306. 306 Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987; 917: 337-40.
307. 307 Hirano K, Ogihara T, Miki M, et al. Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Radic Res 1994; 21: 267-76.
308. 308 Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997; 11: 1157-68.
309. 509 Young PB, Kennedy S, Molloy AM, Scott JM, Weir DG, Kennedy DG. Lipid peroxidation induced in vivo by hyperhomocysteinaemia in pigs. Atherosclerosis 1997; 129: 67-71.
310. 310 Blom HJ, Engelen DPE, Boers GHJ, et al. Lipid peroxidation in homocysteinaemia. J Inherit Metab Dis 1992; 15: 419-22.
311. 311 Dudman NPB, Wilcken DEL, Stocker R. Circulating lipid hydroperoxide levels in human hyperhomocysteinemia -relevant to development of arteriosclerosis. Arterioscler Thromb 1993; 13: 512-6.
312. 312 Blom HJ, Kleinveld HA, Boers GHJ, et al. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur J Clin Invest 1995; 25; 149-54.
313. 313 Córdoba-Porras A, Sanchez-Quesada JL, González-Sastre F, Ordónez-Llanos J, Blanco-Vaca F. Susceptibility of plasma low-and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med 1996; 74: 771-6.
314. 314 Halvorsen B, Brude I, Drevon CA, et al. Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. J Lipid Res 1996; 37: 1591-6000.
315. 315 Dumagala TB, Libura M, Szczeklik A. Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation. Thromb Res 1997; 87: 411-6.
316. 316 Tsai JC, Wang H, Perella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146-53.
317. 317 Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease - enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-81.
318. 318 Nishio E, Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: a possible role for hydrogen peroxide. Br J Pharmacol 1997; 122: 269-74.
319. 319 Tang LL, Mamotte CDS, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998; 136: 169-73.
320. 320 Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol 1998; 274: C396-C405.
321. 321 Dalton ML, Gadson PF, Wrenn RW, Rosenquist TH. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703-11.
322. 322 Jourdheuil-Rahmani D, Rolland PH, Rosset E, Branchereau A, Garcon D. Homocysteine induces synthesis of a serine elastase in arterial smooth muscle cells from multi-organ donors. Cardiovasc Res 1997; 34: 597-602.
323. 323 Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996; 121: 231-43.
324. 324 Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria -evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1400-6.
325. 325 Coppola A, Albisinni R, Madonna P, Pagano A, Cerbone AM, Di Minno G. Platelet and monocyte variables in homocystinuria due to cystathionine-β-synthase deficiency. Haematologica 1997; 82: 189-90.
326. 326 Uhlemann ER, TenPas JH, Lucky AW, Schulman JD, Mudd SH, Shulman NR. Platelet survival and morphology in homocystinuria due to cystathionine synthase deficiency. N Engl J Med 1976; 295: 1283-6.
327. 327 Hill-Zobell RL, Pyeritz RE, Scheffel U, et al. Kinetics and distribution of 111Indium-labeled platelets in patients with homocystinuria. N Engl J Med 1982; 307: 781-6.
328. 328 Ratnoff OD. Activation of Hageman factor by L-homocystine. Science 1968; 162: 1007-9.
329. 329 Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci 1992; 89: 10193-7.
330. 330 Kyrle PA, Stümpflen A, Hirschl M, et al. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thromb Haemost 1997; 78: 1327-31.
331. 331 Blom HJ, van der Molen EF. Pathobiochemical implications of hyperhomocysteinemia. Fibrinolysis 1994; 8: 86-7.
332. 332 Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10 098-103.
333. 333 Montalescot G, Ankri A, Chadefaux-Vekemans B, et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol 1997; 60: 295-300.
334. 334 A, Brook R, Tavendale R, Tunstall-Pedoe. Homocysteine and coronary risk in the general population: analysis from the Scottish Heart Health Study and Scottish Monica surveys [abstract]. Eur Heart J 1998; 19: 213.
335. 335 Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25: 1924-30.
336. 336 Chasan-Taber L, Selhub J, Rosenberg IH, et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15: 136-43.
337. 337 Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
338. 338 Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
339. 339 Folsom AR, Nieto JF, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphism, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-10.
340. 340 Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-41.
341. 341 de Jona SC, Stehouwer CDA, van den Berg M, Geurts TW, Rauwerda JA. Normohomocysteinemia and vitamin-treated hyperhomocysteinemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease [abstract]. Neth J Med 1998; 52: S41-S42.
342. 342 Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. Br Med J 1994; 308: 363-6.
343. 343 Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997; 79: 799-801.
344. 344 Koehler KM, Pareo-Tubbeh SL, Romero LJ, Baumgartner RN, Garry PJ. Folate nutrition and older adults: challenges and opportunities. J Am Diet Assoc 1997; 97: 167-73.
345. 345 Ness A, Powles JW. Fruit and vegetables, and cardiovascular disease: a review, Int J Epidemiol 1997; 26: 1-13.
346. 346 Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996; 275: 1893-6.
347. 347 Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279: 359-64.
348. 348 Wilcken DEL, Wang XL. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherited Metab Dis 1997; 20: 295-300.
349. 349 Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inemia. Lancet 1998; 351: 263.
350. 350 Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998; 98: 196-9.
351. 351 Mudd SH, Havlik R, Levy HL, McKusick VA, Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet 1981; 33: 883-93.
352. 352 Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteniemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
353. 353 Kozich V, Kraus E, de Franchis R, et al. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine beta-synthase alleles at the molecular level. Hum Mol Genet 1995; 4: 623-9.
354. 354 Evers S, Koch HG, Grotemeyer KH, Ullrich K, Deufel T, Harms E. Hyperhomocysteinemia in ischemic stroke is not due to mutations in the cystathiomne beta-synthase gene. Cerebrovasc Dis 1996; 6 (Suppl. 2): 19.
355. 355 Whitehead AS, Ward P, Tan S et al. The molecular genetics of homocystinuria, hyperhomocysteinemia, and premature vascular disease in Ireland. In: Mato JM, Caballero A, eds. Methionine Metabolism: Molecular Mechanisms and Clinical Implications. Madrid: Bouncopy, 1994; 79-83.
356. 356 Brattström L, Wilcken DEL, Öhrvik J, Brudin L. The common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease - the result of a meta analysis. Circulation 1998; 2520-6.
357. 357 Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
358. 358 van der Put NMJ, Steegers-Theunissen RPM, Frosst P et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1.
359. 359 Harmon DL, Woodside JV, Yarnell JWG et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 1996; 89: 571-7.
360. 360 Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation 1996; 94: 1812-4.
361. 361 Ma J, Stampfer MJ, Hennekens CH et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.
362. 362 Deloughery TG, Evans A, Sadeghi A et al. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996; 94: 3074-8.
363. 363 Verhoef P, Kok FJ, Kluijtmans LJ et al. The 677C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 132: 105-13.
364. 364 Kluijtmans LAJ, Kastelein JJP, Lindemans J et al. Thermolabile methylenetetrahydrofolate reduetase in coronary artery disease. Circulation 1997; 96: 2573-7.
365. 365 Christensen B, Frossl P, Lussier-Cacan S et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 569-73.
366. 366 Schwartz SM, Siscovick DS, Malinow MR et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-7.
367. 367 Legnani C, Palareti G, Grauso F et al. Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala (223) Val MTHFR) in patients with inherited thrombophilic coagulation defects. Arterioscler Thromb Vasc Biol 1998; 17: 2924-9.
368. 368 Arai K, Yamasaki Y, Kajimoto Y et al. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM. Diabetes 1997; 46: 2102-4.
369. 369 Lalouschek W, Aull S, Korninger I, et al, 677C to T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and plasma homocyst(e)ine levels in patients with TIA or minor stroke. J Neurol Sci 1998; 165: 156-62.
370. 370 Gallagher PM, Meleady R, Shields DC et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94: 2154-8.
371. 371 Adams M, Smith PD, Martin D, Thompson JR, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM 1996; 89: 437-44.
372. 372 Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996; 121: 293-4.
373. 373 Wilcken DEL, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol 1996; 16: 878-82.
374. 374 de Franchis R, Mancini FP, D'Angelo A et al. Elevated total plasma homocysteine and 677C→T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease [letter]. Am J Hum Genet 1996; 59: 262-4.
375. 375 Narang R, Callaghan G, Haider AW, Davies GJ, Tuddenham EGD. Methylenetetrahydrofolate reductase mutation and coronary artery disease. Circulation 1996; 94: 2322-3.
376. 376 Brulhart MC, Dussoix P, Ruiz J, Passa P, Froguel P, James RW. The (Ala-Val) mutation of methylenetetrahydrofolate reductase as a genetic risk factor for vascular disease in noninsulin-dependent diabetic patients. Am J Hum Genet 1997; 60: 228-9.
377. 377 van Bockxmeer FM, Mamotte CDS, Vusikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21-3.
378. 378 Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis 1997; 128: 107-12.
379. 379 Morita H, Taguchi J, Kurihara H et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032-6.
380. 380 Verhoef P, Rimm EB, Hunter DJ et al. Methylenetetrahydrofolate reductase polymorphism, diet, and risk of coronary heart disease among men. 16th International Congress of Nutrition. July 27-August 1, 1997. Montreal, Canada. (Abstract) PW3.12.
381. 381 Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA Project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism. Br J Haematol 1997; 97: 804-6.
382. 382 Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997; 28: 1739-43.
383. 383 Salden A, Keeney S, Hay CR, Cumming AM. The C677T MTHFR variant and the risk of venous thrombosis. Br J Haematol 1997; 99: 464-72.
384. 384 Reinhardt D, Sigusch HH, Vogt SF, Farker K, Muller S, Hoffmann A. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur J Clin Invest 1997; 28: 20-3.
385. 385 Abbate R, Sardi I, Pepe G et al. The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb Haemost 1998; 79: 727-30.
386. 386 Ou T, Yamakawa-Kobayashi K, Arinami T et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998; 137: 23-8.
387. 387 Kostulas K, Crisby M, Huang WX et al. A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. Eur J Clin Invent 1998; 28: 285-9.
388. 388 Nakata Y, Katsuya T, Takami S et al. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens 1998; 11: 1019-23.
389. 389 Girelli D, Friso S, Trabetti E et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from Northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental Interaction. Blood 1998; 91: 4158-63.